D. Phung

467 total citations
25 papers, 328 citations indexed

About

D. Phung is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, D. Phung has authored 25 papers receiving a total of 328 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in D. Phung's work include Prostate Cancer Treatment and Research (17 papers), Radiopharmaceutical Chemistry and Applications (8 papers) and Prostate Cancer Diagnosis and Treatment (6 papers). D. Phung is often cited by papers focused on Prostate Cancer Treatment and Research (17 papers), Radiopharmaceutical Chemistry and Applications (8 papers) and Prostate Cancer Diagnosis and Treatment (6 papers). D. Phung collaborates with scholars based in United States, Netherlands and France. D. Phung's co-authors include Bertrand Tombal, Tomasz M. Beer, Andrew J. Armstrong, Yohann Loriot, Sarang Abhyankar, Andrew Krivoshik, Celestia S. Higano, Po‐Han Lin, Cora N. Sternberg and C. Sternberg and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

D. Phung

22 papers receiving 324 citations

Peers

Countries citing papers authored by D. Phung

Since Specialization

Citations

This map shows the geographic impact of D. Phung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Phung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Phung more than expected).

Fields of papers citing papers by D. Phung

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Phung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Phung. The network helps show where D. Phung may publish in the future.

Co-authorship network of co-authors of D. Phung

This figure shows the co-authorship network connecting the top 25 collaborators of D. Phung. A scholar is included among the top collaborators of D. Phung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Phung. D. Phung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Intravenously administered LV-169 delivers a functional BCMA-CAR transgene to niche-resident T cells and leads to elimination of disseminated myeloma in MHC-deficient NSG mice 2025 ·Blood ·Stephen J. Russell, (unknown), Nandakumar Packiriswamy, Timothy S. Carey, (unknown), (unknown), (unknown), (unknown), (unknown), Hamid Salimi, Thipparat Suwanmanee, D. Phung, Karina Krotova, Rianna Vandergaast, (unknown), Edward L. Briercheck, Eric L. Smith, (unknown), Kah-Whye Peng	0
2	1460P GALLANT-1: GB1211 galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) 2023 ·Annals of Oncology ·Francisco Aparisi, Enriqueta Felip, Éric Pichon, Enric Carcereny, (unknown), (unknown), T Sethi, Bertil Lindmark, Robert J. Slack, Alison C. MacKinnon, Vassilios Aslanis, D. Phung, (unknown), (unknown), Gayle Ross, Linda Basse, (unknown)	1
3	Evaluation of S201086/GLPG1972, an ADAMTS-5 inhibitor, for the treatment of knee osteoarthritis in ROCCELLA: a phase 2 randomized clinical trial 2023 ·Osteoarthritis and Cartilage ·Thomas J. Schnitzer, María Pueyo, H. Deckx, Ellen van der Aar, (unknown), (unknown), (unknown), (unknown), D. Phung, (unknown), (unknown), K. Müller, Marc C. Hochberg, Henning Bliddal, W. Wirth, F. Eckstein, Philip G. Conaghan	26
4	Efficacy and safety of s201086/GLPG1972, an ADAMTS-5 inhibitor, in patients with knee osteoarthritis: roccella, a 52-week, randomized, double-blind, dose-ranging phase 2 study 2021 ·Osteoarthritis and Cartilage ·Thomas J. Schnitzer, María Pueyo, H. Deckx, Ellen van der Aar, (unknown), Sandra S. Hatch, (unknown), (unknown), D. Phung, (unknown), (unknown), (unknown), Mark S. Hochberg, Henning Bliddal, F. Eckstein, Philip G. Conaghan	5
5	Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer 2018 ·Annals of Oncology ·Andrew J. Armstrong, Po‐Han Lin, Celestia S. Higano, Cora N. Sternberg, Guru Sonpavde, Bertrand Tombal, Arnoud J. Templeton, Karim Fizazi, D. Phung, (unknown), Andrew Krivoshik, Tomasz M. Beer	49
6	A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): Results of PROSPER by age and region 2018 ·Annals of Oncology ·Karim Fizazi, Maha Hussain, Fred Saad, Neal D. Shore, Ugo De Giorgi, Eleni Efstathiou, Ubirajara Ferreira, (unknown), Katarzyna Madziarska, Mohammed Al-Adhami, Katharina Modelska, D. Phung, Joyce Steinberg, Cora N. Sternberg	1
7	Prostate-specific antigen (PSA) response in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC) treated with enzalutamide (ENZA): Results from PROSPER 2018 ·European Urology Supplements ·Cora N. Sternberg, Karim Fizazi, Fred Saad, Per Rathenborg, Neal D. Shore, Eren Demirhan, Katharina Modelska, D. Phung, Andrew Krivoshik, Maha Hussain	0
8	Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL 2017 ·Prostate Cancer and Prostatic Diseases ·Alan H. Bryce, Joshi J. Alumkal, Andrew J. Armstrong, Celestia S. Higano, Peter Iversen, Cora N. Sternberg, Dana E. Rathkopf, Yohann Loriot, Johann S. de Bono, Bertrand Tombal, Sarang Abhyankar, Po‐Han Lin, Andrew Krivoshik, D. Phung, Tomasz M. Beer	71
9	Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials 2017 ·Prostate Cancer and Prostatic Diseases ·Fred Saad, Cristina Ivanescu, D. Phung, Yohann Loriot, Sarang Abhyankar, Tomasz M. Beer, Bertrand Tombal, Stefan Holmström	42
10	A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects 2017 ·Journal of Clinical Pharmacy and Therapeutics ·Walter Krauwinkel, (unknown), Jan van Dijk, Serghei Popa, Taoufik Ouatas, Michiel S. de Vries, D. Phung, Jacqueline A. Gibbons, Joyce Mordenti, Lyudmila Mateva	9
11	Enhancing Interpretation of Patient-Reported Outcome Scores Through Intuitive Metrics: An Example from Prostate Cancer 2016 ·Value in Health ·(unknown), Jean Paty, (unknown), Chad Gwaltney, (unknown), D. Phung, Stefan Holmström	1
12	Fatigue in men with metastatic castration-resistant prostate cancer treated with enzalutamide: data from randomised clinical trials 2016 ·Annals of Oncology ·S. Chowdhury, Neal D. Shore, Fred Saad, Celestia S. Higano, Karim Fizazi, Peter Iversen, K. Miller, Axel Heidenreich, Takeshi Ueda, (unknown), D. Phung, Andrew Krivoshik, (unknown), Kaijie Wu, Bertrand Tombal	2
13	EMBARK: A phase 3, randomized, efficacy and safety study of enzalutamide plus leuprolide, enzalutamide monotherapy and placebo plus leuprolide in men with high-risk nonmetastatic prostate cancer progressing after definitive therapy 2016 ·Annals of Oncology ·K. Miller, Peter Mulders, Stephen J. Freedland, Howard I. Scher, Neal D. Shore, (unknown), Andrew Krivoshik, D. Phung, Katharina Modelska, Peter T. Scardino	2
14	Health-Related Quality Of Life (Hrqol) Benefits Of Enzalutamide In Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc): An In-Depth Analysis Of Eq-5d Data From The Prevail Trial 2015 ·Value in Health ·Nancy Devlin, Michael Herdman, Marco Pavesi, D. Phung, (unknown), (unknown), Bertrand Tombal, Yohann Loriot, Cristina Ivanescu, Teresa Parli, (unknown), Stefan Holmström	1
15	Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL 2015 ·Annals of Oncology ·Julie N. Graff, G. Baciarello, Andrew J. Armstrong, (unknown), Pernille Iversen, Thomas W. Flaig, David Forer, Teresa Parli, D. Phung, Bertrand Tombal, Tomasz M. Beer, C. Sternberg	86
16	Impact Of Enzalutamide or Abiraterone Acetate + Prednisone (Abp) on Quality Of Life (Qol) In The Treatment of Metastatic Castration-Resistant Prostate Cancer (mcrpc) That Has Progressed on Or After Doxetaxel: A Comparative Effectiveness Study 2015 ·Value in Health ·David Cella, Cristina Ivanescu, D. Phung, Harry H. Mansbach, Stefan Holmström, (unknown)	2
17	Skeletal-Related Events (SRES) Impact Significantly the Health-Related Quality of Life (HRQOL) of Chemo-Naive Men With Metastatic Castration Resistant Prostate Cancer (MCRPC) 2014 ·Value in Health ·Cristina Ivanescu, D. Phung, Yohann Loriot, Fred Saad, Harry H. Mansbach, Tomasz M. Beer, Bertrand Tombal, Stefan Holmström	1
18	674 Enzalutamide monotherapy: Results from a phase 2 study in hormone naive prostate cancer patients 2013 ·European Urology Supplements ·Bertrand Tombal, Michael Borre, Per Rathenborg, Patrick Werbrouck, Axel Heidenreich, Peter Iversen, Edwina Baskin-Bey, Frank Perabo, D. Phung, Mitchell R. Smith	1
19	The effect of ZD4054 on bone metastasis in patients with M1 hormone-resistant prostate cancer 2008 ·Data Archiving and Networked Services (DANS) ·Bernard A. Zonnenberg, Michael Borre, Philippe Beuzeboc, Heather Payne, Stéphane Culine, (unknown), D. Phung, Nicholas D. James	1
20	3LB ZD4054, a potent, specific endothelin A receptor antagonist, improves overall survival in pain-free or mildly symptomatic patients with hormone-resistant prostate cancer (HRPC) and bone metastases 2007 ·European Journal of Cancer Supplements ·Nicholas D. James, Michael Borre, Bernard A. Zonnenberg, Philippe Beuzeboc, (unknown), D. Phung, Nancy A. Dawson	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact